Results 81 to 90 of about 8,893 (235)

What Are the Impacts of GLP‐1 Drugs in Patients Needing Head/Neck Surgery?

The Laryngoscope, EarlyView.
Chelsea Gelboin‐Burkhart, Liam Gallagher, Bridget Ebert, Samir S. Khariwala   +3 more
wiley   +1 more source

Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity [PDF]

Introduction People with type 2 diabetes are at heightened risk for severe outcomes related to COVID-19 infection, including hospitalization, intensive care unit admission, and mortality.
Abrahamsen, Trine J., Alexander, G. Caleb, Buse, John B., Chute, Christopher G., Haendel, Melissa, Hong, Stephanie S., Kahkoska, Anna R., Klein, Klara R., Kvist, Kajsa, Mehta, Hemalkumar, Moffitt, Richard, Stürmer, Til   +11 more
core   +2 more sources

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes [PDF]

, 2018
Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk ...
Considine, Robert V., Goodwill, Adam, Green, Mark A., Hamilton, LaTonya, Hutchins, Gary D., Mather, Kieren J., Mathias, Carla, Patel, Niral A., Territo, Wendy, Tune, Johnathan D.   +9 more
core   +1 more source

Construction of a prognostic assessment model for diabetic nephropathy based on serum fibrinogen and renal tissue IFTA score

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Objective To explore the association between serum fibrinogen (FIB) and clinicopathological features and renal prognosis in type 2 diabetic nephropathy (T2DN), and develop a web‐based dynamic model to predict renal progression. Methods This paper retrospectively enrolled 173 biopsy‐proven T2DN patients and stratified them by the optimal FIB ...
Lin Ning, Xiaohong Zhang, Yuan Fang, Mengjie Weng, Yongjie Zhuo, Jianxin Wan   +5 more
wiley   +1 more source

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity

Translation
Background: The Centers for Disease Control and Prevention (CDC) reports that 42% of adults in the United States (US) are obese, and 10% are severely obese. Obesity has many known associated health risks, and successful treatment decreases those risks. Management always includes diet and lifestyle changes and drug therapy can improve weight loss.
Andrew Overholser, Eric Czech, Linda Speer, Joel Wilson, Alex Overholser   +4 more
openaire   +3 more sources

Endogenous GIP signaling is indispensable for DPP‐4 inhibitor‐mediated metabolic control in mice

Journal of Diabetes Investigation, EarlyView.
This study reveals that the metabolic benefits of DPP‐4 inhibitors, including improved glucose tolerance and reduced body weight, are completely abolished in GIP receptor‐deficient mice. These findings establish that endogenous GIP signaling, rather than GLP‐1, is the indispensable key player for the efficacy of this drug class.
Saki Kubota‐Okamoto, Sodai Kubota, Hiromi Tsuchida, Yanyan Liu, Seiya Banno, Toshinori Imaizumi, Taro Fujisawa, Yoshihiro Takahashi, Takehiro Kato, Yukio Horikawa, Katsumi Iizuka, Takaaki Murakami, Yuuka Fujiwara, Hitoshi Kuwata, Yuji Yamazaki, Yutaka Seino, Shin Tsunekawa, Daisuke Yabe   +17 more
wiley   +1 more source

Crossover studies can help the individualisation of care in type 2 diabetes:the MASTERMIND approach [PDF]

, 2016
-The MASTERMIND consortium is funded by a grant from the Medical Research ...
American Diabetes Association, Jones, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, Nikles, Pearson   +5 more
core   +2 more sources

Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials

Journal of Diabetes
Background The cardioprotective effects of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA)‐based therapies in nondiabetic individuals with overweight or obesity remain underexplored.
Yue Yin, Minghan Zhang, Qiuyu Cao, Lin Lin, Jieli Lu, Yufang Bi, Yuhong Chen   +6 more
doaj   +1 more source

Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence

Obesity Reviews, EarlyView.
ABSTRACT Next‐generation incretin therapies, including semaglutide and tirzepatide, have transformed obesity and Type 2 diabetes management. However, evidence‐based nutritional strategies to support safe and effective use of these agents remain limited.
Marie Spreckley, Cara F. Ruggiero, Adrian Brown   +2 more
wiley   +1 more source

Engineering Marker‐Free Lettuce Chloroplast Genome to Express Functional Glucagon‐Like Peptide‐1 Receptor Agonists Exenatide and Lixisenatide

Plant Biotechnology Journal, EarlyView.
Engineering of marker‐free lettuce chloroplast genome to express CTB‐Exenatide and CTB‐Lixisenatide for oral delivery. Upper panel: Chemically synthesised exenatide or lixisenatide require expensive production, purification, refrigeration and invasive delivery methods.
Rahul Singh, Henry Daniell
wiley   +1 more source